Cuprizone short-term exposure: astrocytic IL-6 activation and behavioral changes relevant to psychosis.
about
Preclinical characterization of DUOC-01, a cell therapy product derived from banked umbilical cord blood for use as an adjuvant to umbilical cord blood transplantation for treatment of inherited metabolic diseases.Glial modulators as potential treatments of psychostimulant abuseDimensional assessment of behavioral changes in the cuprizone short-term exposure model for psychosisMolecular substrates of schizophrenia: homeostatic signaling to connectivityNeuronal copper homeostasis susceptibility by genetic defects in dysbindin, a schizophrenia susceptibility factor.In vivo markers of inflammatory response in recent-onset schizophrenia: a combined study using [(11)C]DPA-713 PET and analysis of CSF and plasma.Comparison of serum Concentration of Se, Pb, Mg, Cu, Zn, between MS patients and healthy controls.Behavioral sequelae of astrocyte dysfunction: focus on animal models of schizophrenia.Anti-inflammatory Effect of Astaxanthin on the Sickness Behavior Induced by Diabetes Mellitus.Procyanidin B2 attenuates neurological deficits and blood-brain barrier disruption in a rat model of cerebral ischemia.Functional antagonism of sphingosine-1-phosphate receptor 1 prevents cuprizone-induced demyelination.N-acetylcysteine attenuates the cuprizone-induced behavioral changes and oligodendrocyte loss in male C57BL/7 mice via its anti-inflammation actions.Brain metabolite changes in subcortical regions after exposure to cuprizone for 6 weeks: potential implications for schizophrenia.Differences in iron and manganese concentration may confound the measurement of myelin from R1 and R2 relaxation rates in studies of dysmyelination.Chronic phencyclidine induces inflammatory responses and activates GSK3β in mice.
P2860
Q27309955-0675182A-B3DB-4F77-9E0C-42717FF93856Q28307030-324D6486-6251-4E4C-809A-D60072A157F7Q30355377-76794970-9DB2-42F4-95F5-3B42109E10D4Q30383611-1B8F9D3E-B172-4BBD-AFA4-B0DD97A37EEAQ36065482-B1210172-4B90-4513-AF88-BEEB04313AF9Q36915357-FE3897CD-8404-4F12-93AC-B0C0F4E4C6EDQ37316908-21F71231-64A0-40DC-9699-2A1CE5DF18DCQ38281865-747A71A3-3092-43ED-B125-99762081F913Q40942272-8B502838-33BF-4C2A-AAAC-C6F15D073CCEQ46692435-C6285965-F13E-4B15-9A68-9880F181286EQ47343678-D8AC5E22-E65A-4216-89E6-AE7DF075C067Q47578437-7BFCB2BB-0A32-4E4F-8AA9-83672A6AF961Q47795229-38508F56-A1A8-4937-93DC-FB6C75A4598FQ48713239-D0D23757-56D0-45FB-B481-7E3F77284F16Q50778063-2F498877-E3FE-40BF-A442-5500640AC709
P2860
Cuprizone short-term exposure: astrocytic IL-6 activation and behavioral changes relevant to psychosis.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Cuprizone short-term exposure: ...... changes relevant to psychosis.
@ast
Cuprizone short-term exposure: ...... changes relevant to psychosis.
@en
type
label
Cuprizone short-term exposure: ...... changes relevant to psychosis.
@ast
Cuprizone short-term exposure: ...... changes relevant to psychosis.
@en
prefLabel
Cuprizone short-term exposure: ...... changes relevant to psychosis.
@ast
Cuprizone short-term exposure: ...... changes relevant to psychosis.
@en
P2093
P2860
P1476
Cuprizone short-term exposure: ...... changes relevant to psychosis.
@en
P2093
Akira Sawa
Atsushi Fukunari
Hiromitsu Ohzeki
Hiroshi Yasumatsu
Kana Takemoto
Keiko Miwa
Kinya Okada
Makoto Tamura
Masaki Sakaue
Shin-ichi Kano
P2860
P356
10.1016/J.NBD.2013.07.003
P50
P577
2013-07-16T00:00:00Z